ATXA Therapeutics Founder & CEO Receives 2024 NovaUCD Innovation Award

Professor Therese Kinsella, founder and CEO of ATXA Therapeutics, has been named the recipient of the 2024 NovaUCD Innovation Award....

ATXA Therapeutics Publishes Results of Phase 1 First-in-Human Study Evaluating the Safety & Tolerability of NTP42 in Healthy Volunteers

ATXA Therapeutics have today published a new paper in Frontiers in Pharmacology detailing results of its lead drug candidate NTP42 in a...

ATXA Therapeutics to Participate in Bio€quity Europe 2023

ATXA Therapeutics will be attending the 23rd Bio€quity Europe Conference, due to be held from May 14 – 16, 2023, in Dublin’s Convention...

ATXA to Present at ATS International Conference 2023

ATXA will present data from a First-in-Human (FIH) Phase I trial of NTP42:KVA4, a novel formulation of its lead clinical candidate NTP42...

NTP42 Demonstrates Key Cardioprotective Benefits in Newly-published Preclinical Findings

ATXA Therapeutics have today published a new paper detailing results of its lead drug candidate NTP42 in preclinical models of pulmonary...

ATXA Therapeutics receives Funding through the European Innovation Council Accelerator Programme

ATXA Therapeutics Limited (ATXA) is delighted to announce that it is honoured to receive grant and equity funding through the prestigious...

ATXA Presentation at ERS International Congress 2022

ATXA presented preclinical efficacy results of its lead drug candidate NTP42 for the treatment of pulmonary arterial hypertension (PAH)...

European Commission publish article on ATXA's PAH-HOPE project

The EU Commission has published a "Results in Brief" article on ATXA Therapeutics' EU-funded PAH-HOPE project. Entitled "New Hope for...

ATXA Presentation at ESC Congress 2021

ATXA presented preclinical efficacy results of its lead drug candidate NTP42 for treatment of PAH at the European Society of Cardiology...

Newly-published preclinical findings for ATXA Therapeutics' NTP42

ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a further preclinical model of...

World Orphan Drug Virtual Conference

Well done to the ATXA Team, who gave a presentation at the World Orphan Drug Virtual Conference on Monday 17th August. They presented on...

COMPANY UPDATES